-
Affitope PD01A is a potential Vaccine for Parkinson’s
Affiris’ experimental Parkinson’s vaccine, Affitope PD01A, is safe and effectively triggers an immune response against the alpha-synuclein (aSyn) protein, data from a series of four consecutive clinical trials show. The experimental vaccine, Affitope PD01A — a synthetic aSyn-mimicking peptide based on Affiris’ Affitome technology — targets alpha-synuclein by inducing an immune response that generates antibodies specifically against it.
As such, Affitope PD01A has the potential to modify disease progression. Read more about this research here: Potential Parkinson’s Vaccine, Affitope PD01A, Safe and Possibly Effective in Long-term, Phase 1 Trial Series Finds
Are you familiar with Affitope PD01A? Have you considered trying it?
Log in to reply.